The mission of Stage I Diagnostics is to commercialize diagnostic tests that can detect cancers in the earliest stages of the disease. We believe that there is a significant market need for low cost, reliable, early stage screening tests for cancer. Our approach has been to identify proteins directly involved in the metastatic processes of cancer progression and develop simple blood tests for the detection of these proteins in patients. With this panel of blood tests, detection of early stage disease, when treatment options are greater and more effective, is feasible. Currently, the proteins we have developed assays for have been shown to be overexpressed in a number of different cancer types including prostate, ovarian, breast, colorectal, renal, pancreatic, gastric, esophageal, lung, and cervical cancers. Our first assay, for the detection of the type II transmembrane serine protease Hepsin, is being utilized to help determine if a prostate cancer patient is a good candidate for active surveillance, as opposed to more aggressive treatments. We plan to bring the other assays in the panel, along with Hepsin, to market for the early detection of ovarian cancer over the next year.